{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:22:16Z","timestamp":1788880936590,"version":"build-2803163510"},"reference-count":427,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw Medical University, Poland","award":["IDUB.A46B.24.002"],"award-info":[{"award-number":["IDUB.A46B.24.002"]}]},{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Heart failure (HF) remains a major challenge in cardiovascular medicine, contributing to high global rates of hospitalization and mortality. Recent research (2022\u20132025) has emphasized its heterogeneity, highlighting distinct phenotypes\u2014HFpEF, HFmrEF, and HFrEF\u2014driven by mechanisms such as chronic inflammation, myocardial fibrosis, and neurohormonal imbalance. Advances in therapy, particularly with sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor\u2013neprilysin inhibitors (ARNI), and iron supplementation, have reshaped treatment strategies. Moreover, the growing recognition of overlaps between HF and cardiomyopathies such as hypertrophic, Takotsubo, and amyloidosis underscores the need for integrated care. This review summarizes recent findings from leading journals, mapping the evolving understanding of HF pathophysiology and management, and outlining emerging directions for research and clinical practice.<\/jats:p>","DOI":"10.3390\/jcdd12120484","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:32:17Z","timestamp":1765380737000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022\u20132025"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-4357","authenticated-orcid":false,"given":"Micha\u0142","family":"Wilk","sequence":"first","affiliation":[{"name":"Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Tymk\u00f3w","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/ehf2.14456","article-title":"Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey","volume":"10","author":"Abdelhamid","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/ehf2.14422","article-title":"Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction","volume":"10","author":"Ali","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/ehf2.14959","article-title":"IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction","volume":"11","author":"Berger","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ehf2.14572","article-title":"Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: The VITALITY-HFpEF trial","volume":"11","author":"Butler","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ehf2.15111","article-title":"Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction","volume":"12","author":"Augstein","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/ehf2.14336","article-title":"Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction","volume":"10","author":"Cao","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/ehf2.14349","article-title":"Is excessive ventricular irregularity predictive of rehospitalization in patients with permanent AF and HFpEF?","volume":"10","author":"Chaumont","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ehf2.14225","article-title":"Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction","volume":"10","author":"Choy","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ehf2.14739","article-title":"Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction","volume":"11","author":"Crum","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ehf2.14626","article-title":"Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: A meta-analysis","volume":"11","author":"Laborante","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ehf2.15090","article-title":"Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities","volume":"12","author":"Schroen","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/ehf2.14569","article-title":"Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction","volume":"10","author":"Erhardsson","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1002\/ehf2.14913","article-title":"Long-term outcomes of phenoclusters in preclinical heart failure with preserved and mildly reduced ejection fraction","volume":"11","author":"Fazzini","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ehf2.15169","article-title":"The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)","volume":"12","author":"Gajewski","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1002\/ehf2.14983","article-title":"Immune cell profiling of the ICAM1 p.K56M heart failure with preserved ejection fraction risk variant","volume":"11","author":"Gao","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ehf2.15120","article-title":"Electrocardiograph analysis for risk assessment of heart failure with preserved ejection fraction: A deep learning model","volume":"12","author":"Gao","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ehf2.15093","article-title":"Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction","volume":"12","author":"Hamatani","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1002\/ehf2.14748","article-title":"Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction","volume":"11","author":"He","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ehf2.15084","article-title":"Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey","volume":"12","author":"Einarsson","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ehf2.14654","article-title":"An altered plasma lipidome\u2013phenome network characterizes heart failure with preserved ejection fraction","volume":"11","author":"Jovanovic","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/ehf2.14927","article-title":"Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry","volume":"11","author":"Kitao","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/ehf2.14921","article-title":"Do we really need a heart failure with preserved ejection fraction-specific risk stratification strategy?","volume":"11","author":"Kosmala","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ehf2.14368","article-title":"Heart failure with preserved ejection fraction phenogroup classification using machine learning","volume":"10","author":"Kyodo","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/ehf2.14436","article-title":"Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction","volume":"10","author":"Lanzarone","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1002\/ehf2.14415","article-title":"A case report of a patient with heart failure with preserved ejection fraction presented as dysphagia","volume":"10","author":"Leonidou","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ehf2.14421","article-title":"Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: A meta-analysis","volume":"10","author":"Li","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ehf2.14595","article-title":"Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ehf2.15071","article-title":"Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF","volume":"12","author":"Li","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/ehf2.14721","article-title":"Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ehf2.14274","article-title":"Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction","volume":"10","author":"Meng","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ehf2.15060","article-title":"Prognosis of early-stage HFpEF in the community-dwelling elderly: The Northern Shanghai Study","volume":"12","author":"Meng","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ehf2.14699","article-title":"Carbohydrate antigen 125: A useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction","volume":"11","author":"Menghoum","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ehf2.15116","article-title":"Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction","volume":"12","author":"Mourmans","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ehf2.14794","article-title":"Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction","volume":"11","author":"Wolsk","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/ehf2.14419","article-title":"Association of perivascular fat attenuation on computed tomography and heart failure with preserved ejection fraction","volume":"10","author":"Nishihara","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/ehf2.14378","article-title":"Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease","volume":"10","author":"Otaki","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1002\/ehf2.14928","article-title":"Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fraction","volume":"11","author":"Shahim","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ehf2.14302","article-title":"Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality","volume":"10","author":"Shahim","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/ehf2.14770","article-title":"Cardiac sympathetic nerve activity trends after renal denervation in heart failure with preserved ejection fraction","volume":"11","author":"Shiraki","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/ehf2.14808","article-title":"Relationship of interleukin-16 with different phenogroups in acute heart failure with preserved ejection fraction","volume":"11","author":"Tamaki","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1002\/ehf2.14418","article-title":"Trimetazidine in heart failure with preserved ejection fraction: A randomized controlled cross-over trial","volume":"10","author":"Geurkink","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ehf2.14511","article-title":"Association of mild kidney dysfunction with diastolic dysfunction and heart failure with preserved ejection fraction","volume":"11","author":"Vernooij","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/ehf2.15008","article-title":"Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score","volume":"11","author":"Wang","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ehf2.14570","article-title":"Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: An analysis of TOPCAT trial","volume":"11","author":"Wang","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/ehf2.15163","article-title":"Invasive haemodynamic assessment in heart failure with preserved ejection fraction","volume":"12","author":"Wattanachayakul","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1002\/ehf2.14525","article-title":"Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: A prospective cross-over study","volume":"10","author":"Weerts","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ehf2.15179","article-title":"Inter-atrial block as a predictor of adverse outcomes in patients with HFpEF","volume":"12","author":"Weerts","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ehf2.14562","article-title":"Advances in device-based treatment of heart failure with preserved ejection fraction: Evidence from clinical trials","volume":"11","author":"Wu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/ehf2.14798","article-title":"Age-stratified profiles and outcomes of patients with heart failure with preserved ejection fraction","volume":"11","author":"Yamanaka","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/ehf2.14734","article-title":"Low-density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction","volume":"11","author":"Yano","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/ehf2.14447","article-title":"Heart failure with preserved ejection fraction in haemodialysis patients: Prevalence, diagnosis, risk factors, prognosis","volume":"10","author":"Yu","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1002\/ehf2.15033","article-title":"Prediction of 90 day readmission in heart failure with preserved ejection fraction by interpretable machine learning","volume":"11","author":"Zheng","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/ehf2.14897","article-title":"Complexities of treating co-morbidities in heart failure with preserved ejection fraction","volume":"11","author":"Mrak","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_56","first-page":"e011833","article-title":"Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Sequeira","year":"2024","journal-title":"Circ Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in Patients with Heart Failure and Preserved Ejection Fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e011146","DOI":"10.1161\/CIRCHEARTFAILURE.123.011146","article-title":"Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Azzo","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e011962","DOI":"10.1161\/CIRCHEARTFAILURE.124.011962","article-title":"Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients with Heart Failure with Preserved Ejection Fraction","volume":"18","author":"Badrov","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_60","first-page":"116","article-title":"A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure with Preserved Ejection Fraction","volume":"16","author":"Brubaker","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jchf.2023.01.008","article-title":"Atrial Fibrillation Ablation for Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Chieng","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e011792","DOI":"10.1161\/CIRCHEARTFAILURE.124.011792","article-title":"Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure with Preserved Ejection Fraction: Insights From VITALITY-HFpEF","volume":"17","author":"Defilippi","year":"2024","journal-title":"Circ Heart Fail."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to Manage Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.3231","article-title":"Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium","volume":"26","author":"Dhont","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e012020","DOI":"10.1161\/CIRCHEARTFAILURE.124.012020","article-title":"Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction Between Supine Versus Upright Exercise Hemodynamic Testing","volume":"17","author":"Fudim","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e012187","DOI":"10.1161\/CIRCHEARTFAILURE.124.012187","article-title":"Heart Failure with Preserved Ejection Fraction: From a Vascular Perspective","volume":"17","author":"Goudot","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ejhf.3416","article-title":"Differences in heart failure with preserved ejection fraction management between care providers: An international survey","volume":"27","author":"Guidetti","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e011690","DOI":"10.1161\/CIRCHEARTFAILURE.124.011690","article-title":"Modeling Heart Failure with Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell\u2013Derived Cardiac Organoids","volume":"18","author":"Haim","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ejhf.3322","article-title":"Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation","volume":"26","author":"Harada","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ejhf.2895","article-title":"Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study","volume":"25","author":"Horiuchi","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_71","first-page":"2013","article-title":"A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial","volume":"26","author":"Kitzman","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_72","first-page":"1941","article-title":"Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction","volume":"26","author":"Koleini","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jchf.2024.04.027","article-title":"Low Natriuretic Peptide Levels and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction","volume":"12","author":"Kondo","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e010377","DOI":"10.1161\/CIRCHEARTFAILURE.122.010377","article-title":"Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation","volume":"16","author":"Kondo","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e011366","DOI":"10.1161\/CIRCHEARTFAILURE.123.011366","article-title":"Uncovering Unrecognized Heart Failure with Preserved Ejection Fraction Among Individuals with Obesity and Dyspnea","volume":"17","author":"Kosyakovsky","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ejhf.3105","article-title":"Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction","volume":"26","author":"Larson","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ejhf.3225","article-title":"Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention","volume":"26","author":"Lenselink","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102497","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and Safety of Finerenone in Heart Failure with Preserved Ejection Fraction","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The Adipokine Hypothesis of Heart Failure with a Preserved Ejection Fraction","volume":"86","author":"Packer","year":"2025","journal-title":"JACC"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ejhf.3373","article-title":"Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial","volume":"26","author":"Parwani","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e010543","DOI":"10.1161\/CIRCHEARTFAILURE.123.010543","article-title":"Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure with Preserved Ejection Fraction","volume":"16","author":"Rommel","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.2821","article-title":"Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: A non-invasive echocardiographic study","volume":"25","author":"Saito","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e012350","DOI":"10.1161\/CIRCHEARTFAILURE.124.012350","article-title":"Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure with Preserved Ejection Fraction","volume":"18","author":"Saw","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ejhf.2781","article-title":"Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction","volume":"25","author":"Schuster","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e011693","DOI":"10.1161\/CIRCHEARTFAILURE.123.011693","article-title":"Identifying the Mechanisms of a Peripherally Limited Exercise Phenotype in Patients with Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Skow","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e011269","DOI":"10.1161\/CIRCHEARTFAILURE.123.011269","article-title":"Nonpharmacological Approaches to Managing Heart Failure with Preserved Ejection Fraction","volume":"17","author":"Tang","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2023.09.022","article-title":"Impact of Digital Health Technology on Quality of Life in Patients with Heart Failure","volume":"12","author":"Martin","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ejhf.3115","article-title":"Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction","volume":"26","author":"Wu","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e010395","DOI":"10.1161\/CIRCHEARTFAILURE.123.010395","article-title":"Left Ventricular Gene Expression in Heart Failure with Preserved Ejection Fraction\u2014Profibrotic and Proinflammatory Pathways and Genes","volume":"16","author":"Ye","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure","volume":"85","author":"Kramer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/ejhf.3676","article-title":"Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC","volume":"27","author":"Savarese","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jchf.2024.06.006","article-title":"Obesity and Weight Loss Strategies for Patients with Heart Failure","volume":"12","author":"Vest","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_100","first-page":"1952","article-title":"Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER","volume":"26","author":"Abdin","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/ejhf.3043","article-title":"Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial","volume":"25","author":"Bhatt","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ejhf.3000","article-title":"Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER","volume":"25","author":"Butt","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e012437","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ejhf.3180","article-title":"Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jchf.2025.02.003","article-title":"Left Atrial-to-Coronary Sinus Shunting in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"13","author":"Fioretti","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_109","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/ejhf.2948","article-title":"Remote patient management of heart failure across the ejection fraction spectrum: A pre-specified analysis of the TIM-HF2 trial","volume":"25","author":"Kerwagen","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/ejhf.3003","article-title":"Sex differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get with The Guidelines-Heart Failure registry","volume":"25","author":"Keshvani","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/ejhf.3445","article-title":"Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction\u2014The ESC EORP Heart Failure III Registry","volume":"26","author":"Lund","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/ejhf.2977","article-title":"Rationale and design of ENDEAVOR: A sequential phase 2b\u20133 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction","volume":"25","author":"Lund","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejhf.3383","article-title":"Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"27","author":"Matsumoto","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ejhf.3044","article-title":"Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"25","author":"Matsumoto","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/ejhf.3337","article-title":"Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction","volume":"26","author":"Schupp","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ejhf.3230","article-title":"Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry","volume":"26","author":"Settergren","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ejhf.2908","article-title":"Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry","volume":"25","author":"Shahim","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ejhf.3241","article-title":"Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results","volume":"26","author":"Urey","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/ejhf.3352","article-title":"Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.3263","article-title":"Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced\/preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/ehf2.14731","article-title":"Excess renin is attributed to the combination of forward and backward failure in HFrEF","volume":"11","author":"Arfsten","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ehf2.14551","article-title":"Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF","volume":"11","author":"Bergh","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1002\/ehf2.14508","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: A single-centre experience","volume":"10","author":"Blanco","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ehf2.15117","article-title":"Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction","volume":"12","author":"Cho","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ehf2.14476","article-title":"Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction","volume":"11","author":"Christensen","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/ehf2.14805","article-title":"Treatment patterns of patients with worsening heart failure with reduced ejection fraction","volume":"11","author":"Greene","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1002\/ehf2.14549","article-title":"Vericiguat: A fifth cornerstone in the treatment of heart failure with reduced ejection fraction?","volume":"10","author":"Hammer","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1002\/ehf2.14559","article-title":"Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction","volume":"10","author":"Ergin","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/ehf2.14384","article-title":"Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction","volume":"10","author":"Lauder","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1002\/ehf2.14751","article-title":"Eligibility of Asian and European registry patients for phase III trials in heart failure with reduced ejection fraction","volume":"11","author":"Lim","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/ehf2.14430","article-title":"Impact of sleep apnoea on 30 day hospital readmission rate and cost in heart failure with reduced ejection fraction","volume":"10","author":"Mathew","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/ehf2.14473","article-title":"Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: Systematic review","volume":"10","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ehf2.14682","article-title":"Pressure overload is associated with right ventricular dyssynchrony in heart failure with reduced ejection fraction","volume":"11","author":"Monzo","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ehf2.14538","article-title":"Cost\u2013utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy","volume":"11","author":"Narducci","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ehf2.14674","article-title":"Exercise training and high-sensitivity cardiac troponin-I in patients with heart failure with reduced ejection fraction","volume":"11","author":"Riveland","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ehf2.15031","article-title":"Comparison of mouse models of heart failure with reduced ejection fraction","volume":"12","author":"Sayour","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/ehf2.14758","article-title":"Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction","volume":"11","author":"Sherwood","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ehf2.14619","article-title":"Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population","volume":"11","author":"Solymossi","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/ehf2.14689","article-title":"S2I2N0\u20133 score predicts short- and long-term mortality and morbidity in HFrEF: A post-hoc analysis of the GUIDE-IT trial","volume":"11","author":"Sun","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/ehf2.14802","article-title":"Evaluating haemodynamic changes: Vericiguat in patients with heart failure with reduced ejection fraction","volume":"11","author":"Suzuki","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ehf2.14280","article-title":"Diabetic microvascular complications predicts non-heart failure with reduced ejection fraction in type 2 diabetes","volume":"10","author":"Tochiya","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/ehf2.14741","article-title":"Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction","volume":"11","author":"Verheyen","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ehf2.14700","article-title":"Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction","volume":"11","author":"Zhou","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/ehf2.14941","article-title":"Reply to the letter regarding the article \u2018The prevalence, predictors, and outcomes of left ventricular thrombus in HFrEF\u2019","volume":"11","author":"Zhou","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/ehf2.13424","article-title":"Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction","volume":"8","author":"Curran","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ejhf.3147","article-title":"Neuromodulation interventions in the management of heart failure","volume":"26","author":"Abdin","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jchf.2023.11.018","article-title":"Tricuspid Regurgitation and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction","volume":"12","author":"Adamo","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e011173","DOI":"10.1161\/CIRCHEARTFAILURE.123.011173","article-title":"Risk Factors and Outcomes Associated with Heart Failure with Preserved and Reduced Ejection Fraction in People with Chronic Kidney Disease","volume":"17","author":"Bansal","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ejhf.2886","article-title":"Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial","volume":"25","author":"Barat","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e009337","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and Health-Related Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction: Insights From the VICTORIA Trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/ejhf.3378","article-title":"Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry","volume":"26","author":"Cao","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ejhf.2795","article-title":"Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: Data from the Swedish Heart Failure Registry","volume":"25","author":"Cappelletto","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.122.063602","article-title":"Cost-Effectiveness of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial","volume":"148","author":"Chew","year":"2023","journal-title":"Circulation"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ejhf.3131","article-title":"Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling","volume":"26","author":"Dauw","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jchf.2023.01.004","article-title":"Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure with Reduced Ejection Fraction","volume":"11","author":"Dixit","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","article-title":"Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial","volume":"16","author":"Ezekowitz","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ejhf.3258","article-title":"Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes","volume":"26","author":"Grassi","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jchf.2024.05.007","article-title":"Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status","volume":"12","author":"Khan","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jchf.2022.11.007","article-title":"Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, Sex, and Outcomes in Heart Failure with Reduced EF","volume":"11","author":"Lam","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Monzo, L., Bresso, E., Dickstein, K., Pitt, B., Cleland, J.G., Anker, S.D., Lam, C.S., Mehra, M.R., van Veldhuisen, D.J., and Greenberg, B. (2024). Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction. Eur. J. Heart Fail., ejhf.3547.","DOI":"10.1002\/ejhf.3547"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/ejhf.2939","article-title":"Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry","volume":"25","author":"Nguyen","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy","volume":"25","author":"Pieske","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.3501","article-title":"Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial","volume":"27","author":"Reddy","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jchf.2024.07.013","article-title":"Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure Trial","volume":"12","author":"Sears","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jchf.2023.04.015","article-title":"Opportunities and Achievement of Medication Initiation Among Inpatients with Heart Failure with Reduced Ejection Fraction","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ejhf.3081","article-title":"Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ejhf.3156","article-title":"Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach","volume":"26","author":"Tharshana","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/CIRCHEARTFAILURE.122.010278","article-title":"DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients with Heart Failure with Reduced Ejection Fraction","volume":"16","author":"Verma","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jchf.2022.08.023","article-title":"Treatment Differences in Medical Therapy for Heart Failure with Reduced Ejection Fraction Between Sociodemographic Groups","volume":"11","author":"Witting","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ejhf.3232","article-title":"Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes","volume":"26","author":"Zile","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ehf2.15134","article-title":"Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial","volume":"12","author":"Kittipibul","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/ehf2.15308","article-title":"Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists","volume":"12","author":"Jiang","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.3644","article-title":"Cardioprotective effects of semaglutide on isolated human ventricular myocardium","volume":"27","author":"Krammer","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ehf2.15184","article-title":"Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF","volume":"12","author":"Ambrosy","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ehf2.15088","article-title":"Long-term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS-HF study","volume":"12","author":"Amioka","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/ehf2.14381","article-title":"Cardio\u2013renal\u2013metabolic syndrome: Clinical features and dapagliflozin eligibility in a real-world heart failure cohort","volume":"10","author":"Beles","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/ehf2.14313","article-title":"Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure","volume":"10","author":"Bosch","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/ehf2.14830","article-title":"Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): Rationale and design","volume":"11","author":"Carberry","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ehf2.15150","article-title":"Dapagliflozin alleviates high-fat-induced obesity cardiomyopathy by inhibiting ferroptosis","volume":"12","author":"Chen","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ehf2.14297","article-title":"Indirect comparison of SGLT2 inhibitors in patients with established heart failure: Evidence based on Bayesian methods","volume":"10","author":"Chen","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/ehf2.14347","article-title":"Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction","volume":"10","author":"Clemmer","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ehf2.14298","article-title":"The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure","volume":"10","author":"Ji","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ehf2.15049","article-title":"Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED\u2013HEART study","volume":"12","author":"Kocabas","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1002\/ehf2.14470","article-title":"Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%","volume":"10","author":"Kolovos","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1002\/ehf2.14987","article-title":"SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ehf2.14357","article-title":"Impact of diabetes duration on left ventricular mass regression with empagliflozin","volume":"10","author":"Moroney","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/ehf2.14335","article-title":"IGFBP7 and left ventricular mass regression: A sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"10","author":"Puar","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/ehf2.14993","article-title":"Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis","volume":"11","author":"Savage","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/ehf2.14426","article-title":"Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction","volume":"10","author":"Tang","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ehf2.14565","article-title":"Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction","volume":"11","author":"Tsutsui","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ehf2.14351","article-title":"Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling","volume":"10","author":"Verma","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 Inhibitor Use and Risk of Clinical Events in Patients with Cancer Therapy\u2013Related Cardiac Dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e011124","DOI":"10.1161\/CIRCHEARTFAILURE.123.011124","article-title":"Will the SGLT2i Responders Please Stand Up?","volume":"16","author":"Banner","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/ejhf.3423","article-title":"Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm?","volume":"26","author":"Biegus","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/ejhf.2922","article-title":"Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial","volume":"25","author":"Butler","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ejhf.3560","article-title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)","volume":"27","author":"Carberry","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jchf.2024.10.021","article-title":"Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial","volume":"13","author":"Carson","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ejhf.2915","article-title":"Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/ejhf.2982","article-title":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_210","first-page":"1976","article-title":"Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ejhf.3078","article-title":"Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jchf.2023.03.024","article-title":"Utilization Rates of SGLT2 Inhibitors Among Patients with Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease","volume":"11","author":"Hussain","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jchf.2024.04.003","article-title":"Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset with SGLT2i Therapy","volume":"12","author":"Kittipibul","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e010633","DOI":"10.1161\/CIRCHEARTFAILURE.123.010633","article-title":"Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure with Preserved Ejection Fraction: PRESERVED-HF","volume":"16","author":"Lewis","year":"2023","journal-title":"Circ Heart Fail."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaccao.2024.12.004","article-title":"SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics","volume":"7","author":"Mastrangelo","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e009837","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","article-title":"Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ejhf.3184","article-title":"Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER","volume":"26","author":"Peikert","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/ejhf.2999","article-title":"Implementation of sodium\u2013glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be","volume":"25","author":"Pierce","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e011107","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107","article-title":"Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain","volume":"17","author":"Schauer","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e011980","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","article-title":"Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction","volume":"17","author":"Selvaraj","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ejhf.3218","article-title":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction\u2014Results from the EMPULSE trial","volume":"26","author":"Tromp","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium\u2013glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_229","first-page":"1967","article-title":"Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jchf.2024.04.018","article-title":"Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF","volume":"12","author":"Weintraub","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e012373","DOI":"10.1161\/CIRCHEARTFAILURE.124.012373","article-title":"SGLT2 Inhibitors and Their Effect on Metabolism in Patients with Heart Failure","volume":"17","author":"Wiggers","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.3192","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction","volume":"26","author":"Wood","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ehjcvp\/pvaf028","article-title":"Effects of sodium\u2013glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: A systematic review and meta-analysis","volume":"11","author":"Novo","year":"2025","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"102823","DOI":"10.1016\/j.cpcardiol.2024.102823","article-title":"SGLT2 inhibitor therapy in patients with advanced heart failure and reduced ejection fraction","volume":"49","author":"Nuzzi","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ehf2.14558","article-title":"Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril\/valsartan","volume":"11","author":"Butt","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ehf2.15082","article-title":"The in-hospital administration of sacubitril\/valsartan in acute myocardial infarction: A meta-analysis","volume":"12","author":"Improta","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/ehf2.14346","article-title":"Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril\/valsartan","volume":"10","author":"Fabiani","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ehf2.14600","article-title":"Pharmacoutilization and adherence to sacubitril\/valsartan in real world: The REAL.IT study in HFrEF","volume":"11","author":"Iacoviello","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ehf2.14646","article-title":"Improved heart function and cardiac remodelling following sacubitril\/valsartan in acute coronary syndrome with HF","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/ehf2.14344","article-title":"Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril\/valsartan and SGLT2i","volume":"10","author":"Mapelli","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/ehf2.14503","article-title":"Importance of the \u2018area under the curve\u2019 from serial NT-proBNP measurements during treatment with sacubitril\/valsartan","volume":"10","author":"Mohebi","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/ehf2.15145","article-title":"Sacubitril\/valsartan preserves regional cardiac function following myocardial infarction in rats","volume":"12","author":"Bendiksen","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ehf2.14466","article-title":"Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): Design and rationale of the randomized trial","volume":"10","author":"Tajstra","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ehf2.14367","article-title":"Dose titration of sacubitril\/valsartan for heart failure with reduced ejection fraction: A real-world study","volume":"10","author":"Wang","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/ehf2.14076","article-title":"\u201cImpact analysis of heart failure across European countries: An ESC-HFA position paper\u201d and \u201cEchocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan\u201d","volume":"9","author":"Rosano","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jchf.2025.03.010","article-title":"Diuretic De-Escalation in Response to HF Therapy","volume":"13","author":"Biegus","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","article-title":"Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF","volume":"84","author":"Biegus","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin Inhibitors in Heart Failure","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jchf.2024.12.010","article-title":"Effects of Sacubitril\/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF","volume":"13","author":"Kondo","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ejhf.3265","article-title":"Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: The NATRIUM-HF study","volume":"26","author":"Mebazaa","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10741-024-10471-1","article-title":"Sacubitril\/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)","volume":"30","author":"Rajzer","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","article-title":"Sacubitril\/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial","volume":"150","author":"Shaddy","year":"2024","journal-title":"Circulation"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/ejhf.3404","article-title":"Status and timing of angiotensin receptor\u2013neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry","volume":"26","author":"Stolfo","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.3291","article-title":"Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)","volume":"26","author":"Velicki","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2023.05.002","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"82","author":"Ventura","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ehf2.14905","article-title":"Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials","volume":"12","author":"Ahmed","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/ehf2.14276","article-title":"Iron therapy and severe arrhythmias in HFrEF: Rationale, study design, and baseline results of the RESAFE-HF trial","volume":"10","author":"Bakogiannis","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/ehf2.14849","article-title":"Iron deficiency in new onset heart failure: Association with clinical factors and quality of life","volume":"11","author":"Cabrera","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ehf2.14329","article-title":"Magnetic resonance imaging of organ iron before and after correction of iron deficiency in patients with heart failure","volume":"10","author":"Gertler","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/ehf2.14438","article-title":"Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure","volume":"10","author":"Graham","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ehf2.15149","article-title":"Prognostic impact of iron deficiency in new-onset chronic heart failure: Danish Heart Failure Registry insights","volume":"12","author":"Mohamed","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ehf2.14610","article-title":"Relationship between serum iron level and physical function in heart failure patients is lost by presence of diabetes","volume":"11","author":"Ohori","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ehf2.14286","article-title":"Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials","volume":"10","author":"Rosano","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/ehf2.14310","article-title":"Intravenous iron infusion in patients with heart failure: A systematic review and study-level meta-analysis","volume":"10","author":"Salah","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ehf2.14630","article-title":"Improvement in left atrial strain following ferric carboxymaltose in heart failure: An analysis of the Myocardial-IRON trial","volume":"11","author":"Santas","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/ehf2.14724","article-title":"Iron Deficiency and Incident Heart Failure in Older Community-Dwelling Individuals","volume":"11","author":"Sharma","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ehf2.15157","article-title":"Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities","volume":"12","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ejhf.2860","article-title":"Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis","volume":"25","author":"Anker","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ejhf.3051","article-title":"Striving for the \u2018perfect\u2019 definition of iron deficiency in heart failure","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ejhf.3356","article-title":"Iron deficiency and supplementation in patients with heart failure: Results from the IRON-HF international survey","volume":"27","author":"Camilli","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.jacc.2024.03.431","article-title":"Intravenous Iron Repletion for Patients with Heart Failure and Iron Deficiency","volume":"83","author":"Cheema","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ejhf.3534","article-title":"Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure","volume":"27","author":"Pellicori","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ejhf.3504","article-title":"Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial","volume":"27","author":"Foley","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: An updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ejhf.2787","article-title":"Benefits of intravenous iron supplementation in patients with heart failure: Mounting evidence and open questions","volume":"25","author":"Kalogeropoulos","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jchf.2024.05.014","article-title":"Management of Iron Deficiency in Heart Failure","volume":"12","author":"Kido","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.2879","article-title":"Iron deficiency in heart failure: Screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project","volume":"25","author":"Lindberg","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium\u2013glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"e011440","DOI":"10.1161\/CIRCHEARTFAILURE.123.011440","article-title":"Defining Iron Deficiency in Heart Failure: Importance of Transferrin Saturation","volume":"17","author":"Martens","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for Iron Deficiency in Patients with Heart Failure","volume":"79","author":"Masini","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.3348","article-title":"Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID","volume":"27","author":"Nouhravesh","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","article-title":"Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure","volume":"11","author":"Packer","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/ejhf.3238","article-title":"Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron-deficient heart failure","volume":"26","author":"Packer","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ejhf.3237","article-title":"Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure","volume":"26","author":"Packer","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","article-title":"Redefining Iron Deficiency in Patients with Chronic Heart Failure","volume":"150","author":"Packer","year":"2024","journal-title":"Circulation"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/ejhf.2949","article-title":"Prognostic value of three iron deficiency definitions in patients with advanced heart failure","volume":"25","author":"Papadopoulou","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ejhf.3064","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: Any incremental effect?","volume":"25","author":"Savarese","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ehf2.14645","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients","volume":"11","author":"Aaseth","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1002\/ehf2.15045","article-title":"First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia","volume":"11","author":"Ahmad","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/ehf2.15035","article-title":"Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis","volume":"11","author":"Alonso","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ehf2.15061","article-title":"Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis","volume":"12","author":"Amadio","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ehf2.15143","article-title":"A phenomap of TTR amyloidosis to aid diagnostic screening","volume":"12","author":"Antonopoulos","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ehf2.14684","article-title":"Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis","volume":"12","author":"Zampieri","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.14337","article-title":"Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure","volume":"10","author":"Berthelot","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/ehf2.14709","article-title":"Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement","volume":"11","author":"Beuthner","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ehf2.15026","article-title":"Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis","volume":"12","author":"Broussier","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/ehf2.14406","article-title":"Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: A systematic review and meta-analysis","volume":"10","author":"Cantone","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ehf2.14695","article-title":"Too young for an acquired cardiomyopathy? Cobalt metallosis as a cardiac amyloidosis mimicker","volume":"11","author":"Casian","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/ehf2.14815","article-title":"Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy","volume":"11","author":"Dobner","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/ehf2.14350","article-title":"Health-related quality of life among transthyretin amyloid cardiomyopathy patients","volume":"10","author":"Eldhagen","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/ehf2.15013","article-title":"Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography","volume":"11","author":"Ferkh","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ehf2.14622","article-title":"Musculoskeletal co-morbidities in patients with transthyretin amyloid cardiomyopathy: A systematic review","volume":"11","author":"Formiga","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/ehf2.14786","article-title":"Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: The AMY score","volume":"11","author":"Gioia","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ehf2.15112","article-title":"Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction","volume":"12","author":"Healy","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ehf2.15166","article-title":"Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy","volume":"12","author":"Holcman","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/ehf2.14621","article-title":"Invasive haemodynamics at rest and exercise in cardiac amyloidosis","volume":"11","author":"Holt","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ehf2.15016","article-title":"Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty","volume":"12","author":"Izumiya","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/ehf2.14736","article-title":"Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan","volume":"11","author":"Kato","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1002\/ehf2.14975","article-title":"Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis","volume":"11","author":"Kwok","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ehf2.15181","article-title":"The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild-type transthyretin amyloidosis","volume":"12","author":"Ladefoged","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/ehf2.14315","article-title":"Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis","volume":"10","author":"Leo","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ehf2.14567","article-title":"Dapagliflozin treatment and cardiovascular outcome in RBP4\/TTRVal30Met (transthyretin cardiac amyloidosis) mice","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1002\/ehf2.14517","article-title":"Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records","volume":"10","author":"Moya","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/ehf2.14364","article-title":"Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan","volume":"10","author":"Naito","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/ehf2.14852","article-title":"Cardiac amyloidosis is not a single disease: A multiparametric comparison between the light chain and transthyretin forms","volume":"11","author":"Neculae","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/ehf2.15126","article-title":"Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study","volume":"12","author":"Nies","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1002\/ehf2.14937","article-title":"Importance of fourth heart sound and preserved left atrial function in wild-type transthyretin amyloidosis","volume":"11","author":"Ochi","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ehf2.14545","article-title":"Outcome prediction by myocardial external efficiency from 11C-acetate positron emission tomography in cardiac amyloidosis","volume":"11","author":"Rosengren","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ehf2.14543","article-title":"Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy","volume":"11","author":"Sha","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ehf2.15091","article-title":"Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study","volume":"12","author":"Tini","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/ehf2.14710","article-title":"A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis","volume":"11","author":"Usuku","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ehf2.14655","article-title":"Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis","volume":"11","author":"Vereckei","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ehf2.15147","article-title":"Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing\u2014A multicentre study","volume":"12","author":"Willixhofer","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/ehf2.14671","article-title":"Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study","volume":"11","author":"Zaroui","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaccao.2024.07.009","article-title":"Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients with Cardiac Amyloidosis","volume":"6","author":"Aimo","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaccao.2025.02.007","article-title":"Cardiac Biomarkers in Patients with Suspected Amyloid (Transthyretin) Cardiomyopathy","volume":"7","author":"Aimo","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_330","doi-asserted-by":"crossref","unstructured":"Bonfioli, G.B., Tomasoni, D., Vergaro, G., Castiglione, V., Adamo, M., Fabiani, I., Loghin, V., Lombardi, C.M., Nicolai, A., and Metra, M. (2024). The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. Eur. J. Heart Fail., ejhf.3455.","DOI":"10.1002\/ejhf.3455"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.3137","article-title":"Myocardial perfusion in cardiac amyloidosis","volume":"26","author":"Chacko","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","article-title":"Cardiac Troponin in Patients with Light Chain and Transthyretin Cardiac Amyloidosis","volume":"6","author":"Cipriani","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_333","first-page":"e012816","article-title":"High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy","volume":"18","author":"Sinigiani","year":"2025","journal-title":"Circ Heart Fail."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"ejhf.3330","DOI":"10.1002\/ejhf.3330","article-title":"Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction","volume":"26","author":"Drachman","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2024.05.016","article-title":"Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy","volume":"6","author":"Fine","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"e012112","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","article-title":"Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis","volume":"18","author":"Fontana","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jaccao.2025.01.018","article-title":"Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis","volume":"7","author":"Fumagalli","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jacc.2024.01.010","article-title":"Histological Typing in Patients with Cardiac Amyloidosis","volume":"83","author":"McPhail","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaccao.2024.04.002","article-title":"Light-Chain Pericardial Amyloidosis Emerging Alongside Variant Transthyretin Cardiac Amyloidosis","volume":"6","author":"Gunn","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jchf.2023.02.003","article-title":"Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant","volume":"11","author":"Haring","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaccao.2024.05.006","article-title":"Understanding Race, Genotype, and Socioeconomic Status in Transthyretin Amyloid Cardiomyopathy","volume":"6","author":"Martyn","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_345","doi-asserted-by":"crossref","unstructured":"Netti, L., Ioannou, A., Martinez-Naharro, A., Razvi, Y., Porcari, A., Venneri, L., Maestrini, V., Knight, D., Virsinskaite, R., and Rauf, M.U. (2024). Microvascular obstruction in cardiac amyloidosis. Eur. J. Heart Fail., ejhf.3481.","DOI":"10.1002\/ejhf.3481"},{"key":"ref_346","first-page":"2008","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"e012135","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcmg.2025.03.014","article-title":"Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy","volume":"18","author":"Razvi","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jchf.2024.07.003","article-title":"The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared with Transthyretin Amyloidosis","volume":"12","author":"Schilling","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaccao.2024.05.001","article-title":"Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis","volume":"6","author":"Shankar","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ejhf.2823","article-title":"Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: A multicentre network study","volume":"25","author":"Tini","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jchf.2024.03.012","article-title":"Myocardial Mitochondrial Function Is Impaired in Cardiac Light-Chain Amyloidosis Compared to Transthyretin Amyloidosis","volume":"12","author":"Zweck","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","article-title":"Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"6","author":"Witteles","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ehf2.14623","article-title":"Insulin resistance in Takotsubo syndrome","volume":"11","author":"Bruns","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/ehf2.15080","article-title":"Takotsubo cardiomyopathy during armed conflict: A case series","volume":"12","author":"Bruoha","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/ehf2.14394","article-title":"Coronary microvascular dysfunction in Takotsubo syndrome and associations with left ventricular function","volume":"10","author":"Nickander","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/ehf2.14719","article-title":"Takotsubo syndrome and vaccines: A systematic review","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1002\/ehf2.14943","article-title":"Is index of microvascular resistance of Sisyphean utility in Takotsubo syndrome?","volume":"11","author":"Lim","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/ehf2.14713","article-title":"Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: A report from the SWEDEHEART registry","volume":"11","author":"Petursson","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1002\/ehf2.14536","article-title":"Takotsubo syndrome before and during the COVID-19 pandemic in Austria: A retrospective cohort study (TOSCA-19)","volume":"10","author":"Pogran","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ehf2.14652","article-title":"ESCHF-23-00103R1 \u2018Microvascular function and inflammatory activation in Takotsubo cardiomyopathy\u2019","volume":"11","author":"Solberg","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/ehf2.14461","article-title":"Microvascular function and inflammatory activation in Takotsubo cardiomyopathy","volume":"10","author":"Solberg","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"100798","DOI":"10.1016\/j.jacadv.2023.100798","article-title":"Cardiovascular Mortality in Takotsubo Syndrome","volume":"3","author":"Citro","year":"2024","journal-title":"JACC Adv."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/ejhf.3069","article-title":"A machine-learning-based prediction model in patients with takotsubo syndrome: \u2018You can\u2019t stop change any more than you can stop the suns from setting!\u2019","volume":"25","author":"Borovac","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/ejhf.2983","article-title":"Machine learning-based prediction of in-hospital death for patients with takotsubo syndrome: The InterTAK-ML model","volume":"25","author":"Cammann","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ejhf.3264","article-title":"Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jchf.2022.11.001","article-title":"Structural and Functional Brain Changes in Acute Takotsubo Syndrome","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/ejhf.2979","article-title":"State-of-the-art document on optimal contemporary management of cardiomyopathies","volume":"25","author":"Polovina","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.121.055854","article-title":"Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications","volume":"145","author":"Singh","year":"2022","journal-title":"Circulation"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/ehf2.14977","article-title":"Association of liver fibrosis-4 index with adverse outcomes in hypertrophic cardiomyopathy patients","volume":"11","author":"Abdu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ehf2.14882","article-title":"Mavacamten in real-life practice: Initial experience at a hypertrophic cardiomyopathy centre","volume":"12","author":"Abood","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ehf2.14272","article-title":"Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?","volume":"10","author":"Achim","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/ehf2.14906","article-title":"Identification of a novel likely pathogenic TPM1 variant linked to hypertrophic cardiomyopathy in a family with sudden cardiac death","volume":"11","author":"Azimi","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ehf2.14637","article-title":"Natural history and outcomes in paediatric RASopathy-associated hypertrophic cardiomyopathy","volume":"11","author":"Boleti","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/ehf2.14988","article-title":"The D-HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy","volume":"11","author":"Domain","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ehf2.14776","article-title":"Exercise limitation in hypertrophic cardiomyopathy: Combined stress echocardiography and cardiopulmonary exercise test","volume":"11","author":"Erez","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ehf2.15138","article-title":"Considerations for drug trials in hypertrophic cardiomyopathy","volume":"12","author":"Farrant","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ehf2.14962","article-title":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","volume":"12","author":"Filippatos","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/ehf2.14427","article-title":"Hypertrophic obstructive cardiomyopathy caused by Fabry disease: Implications for surgical myectomy","volume":"10","author":"Frustaci","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Damy","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/ehf2.14345","article-title":"Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care","volume":"10","author":"Garmany","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ehf2.15109","article-title":"Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy","volume":"12","author":"Guo","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/ehf2.14481","article-title":"Effects of septal myectomy on left atrial and left ventricular function in obstructive hypertrophic cardiomyopathy","volume":"10","author":"Ha","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/ehf2.15173","article-title":"Trametinib alters contractility of paediatric Noonan syndrome-associated hypertrophic myocardial tissue slices","volume":"12","author":"Hamers","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ehf2.15135","article-title":"Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy","volume":"12","author":"Li","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1002\/ehf2.15065","article-title":"Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study","volume":"11","author":"Lin","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/ehf2.14762","article-title":"Machine learning-driven diagnostic signature provides new insights in clinical management of hypertrophic cardiomyopathy","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/ehf2.14414","article-title":"Effects of bariatric surgery on cardiovascular-related acute care use in patients with hypertrophic cardiomyopathy","volume":"10","author":"Miyashita","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ehf2.14424","article-title":"A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy","volume":"10","author":"Ni","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/ehf2.15004","article-title":"Association of Fibrate use with clinical expression of hypertrophic cardiomyopathy","volume":"11","author":"Park","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ehf2.14707","article-title":"Chlorogenic acid attenuates cardiac hypertrophy via up-regulating Sphingosine-1-phosphate receptor1 to inhibit endoplasmic reticulum stress","volume":"11","author":"Ping","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/ehf2.14775","article-title":"Intramyocardial calcification in apical hypertrophic cardiomyopathy assessed using multimodality imaging: A case series","volume":"11","author":"Radano","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1002\/ehf2.14848","article-title":"Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations","volume":"11","author":"Saul","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/ehf2.14844","article-title":"Different clinical presentation, cardiac morphology and gene mutations in two sisters with hypertrophic cardiomyopathy\u2014A case report","volume":"11","author":"Tayier","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1002\/ehf2.14944","article-title":"Biventricular outflow tract obstruction due to hypertrophy related to compound heterozygous variants in LZTR1","volume":"11","author":"Wang","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1002\/ehf2.15010","article-title":"Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy","volume":"11","author":"Zhang","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"101426","DOI":"10.1016\/j.jacadv.2024.101426","article-title":"Long-Term Impact of Pregnancy on Clinical Outcomes in Individuals with Hypertrophic Cardiomyopathy","volume":"4","author":"Abdeldayem","year":"2025","journal-title":"JACC Adv."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ejhf.3120","article-title":"Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population","volume":"26","author":"Bertero","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacbts.2024.12.016","article-title":"Phenotype-Based Classification of Obstructive Hypertrophic Cardiomyopathy Undergoing Myectomy","volume":"10","author":"Cui","year":"2025","journal-title":"JACC Basic Transl Sci."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacep.2025.02.024","article-title":"Real-World Artificial Intelligence\u2013Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy","volume":"11","author":"Desai","year":"2025","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ejhf.2768","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy\u2014Are beta-blockers blocking part of its shine?","volume":"25","author":"Dominguez","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"e010970","DOI":"10.1161\/CIRCHEARTFAILURE.123.010970","article-title":"Genetic Testing Yield and Clinical Characteristics of Hypertrophic Cardiomyopathy in Understudied Ethnic Groups: Insights From a New Zealand National Registry","volume":"17","author":"Earle","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcmg.2023.05.003","article-title":"Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy","volume":"17","author":"Fahmy","year":"2024","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"e012093","DOI":"10.1161\/CIRCHEARTFAILURE.124.012093","article-title":"New Perspectives on Early Stage Hypertrophic Cardiomyopathy: Measuring What Matters","volume":"17","author":"Goldie","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"101235","DOI":"10.1016\/j.jacadv.2024.101235","article-title":"Long-Term Outcomes of Patients with Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score","volume":"3","author":"Gaballa","year":"2024","journal-title":"JACC Adv."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/ejhf.3413","article-title":"Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2 FPEF score","volume":"26","author":"Laenens","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jchf.2023.07.004","article-title":"Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy","volume":"11","author":"Liang","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ejhf.3546","article-title":"Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning","volume":"27","author":"Lu","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Patients with Nonobstructive Hypertrophic Cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy","volume":"84","author":"Maron","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_412","first-page":"1993","article-title":"Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM","volume":"26","author":"Masri","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy","volume":"84","author":"Masri","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","article-title":"Standard-of-Care Medication Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM","volume":"84","author":"Masri","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"100337","DOI":"10.1016\/j.jacadv.2023.100337","article-title":"Lifetime Clinical Course of Hypertrophic Cardiomyopathy","volume":"2","author":"Maurizi","year":"2023","journal-title":"JACC Adv."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacc.2022.10.027","article-title":"Survival After Septal Reduction in Patients >65 Years Old with Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Mentias","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ejhf.2997","article-title":"Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Moura","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"100899","DOI":"10.1016\/j.jacadv.2024.100899","article-title":"Transcatheter Ablation of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy","volume":"3","author":"Pierri","year":"2024","journal-title":"JACC Adv."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"102496","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/ejhf.3408","article-title":"Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy","volume":"26","author":"Scolari","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jcmg.2022.11.013","article-title":"Apical Aneurysms and Mid\u2013Left Ventricular Obstruction in Hypertrophic Cardiomyopathy","volume":"16","author":"Sherrid","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"101195","DOI":"10.1016\/j.jacadv.2024.101195","article-title":"Clinical Course and Treatment of Patients with Apical Aneurysms Due to Hypertrophic Cardiomyopathy","volume":"3","author":"Sherrid","year":"2024","journal-title":"JACC Adv."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy","volume":"84","author":"Sherrod","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"e012393","DOI":"10.1161\/CIRCHEARTFAILURE.124.012393","article-title":"Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial","volume":"18","author":"Topriceanu","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"100308","DOI":"10.1016\/j.jacadv.2023.100308","article-title":"Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy","volume":"2","author":"Troy","year":"2023","journal-title":"JACC Adv."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/12\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:20:46Z","timestamp":1767691246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/12\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":427,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcdd12120484"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12120484","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}